Vanderbilt Health is leading an expanded national clinical trial, REVERSE LC, to test whether the immunomodulatory drug baricitinib can improve persistent neurological and cardiopulmonary symptoms of long COVID. Enrollment is now expanding to 13 additional sites across the U.S. Led by Wes Ely, MD, MPH, with expansion coordinated by Sean Collins, MD, MSc, the study aims to deliver urgently needed evidence to treat what Ely calls a “massive yet under recognized global public health problem.”